Beranda › Dermatitis Atopik (Eksim) › Alabama
Uji klinis Dermatitis Atopik (Eksim) di Alabama
9 studi untuk Dermatitis Atopik (Eksim) mencari peserta di lokasi di Alabama.
Kota di Alabama
Teks studi resmi (Bahasa Inggris)
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Cahaba Dermatology & Skin Health Center- Site Number : 8400006, Birmingham
- River Region Dermatology and Laser- Site Number : 8400041, Montgomery
Menerima pesertaStudi observasional
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07290803Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Birmingham
- Novartis Investigative Site, Birmingham
Menerima pesertaFase 2
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Birmingham
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07298395First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
- Cahaba Dermatology & Skin Health Center, LLC, Birmingham
Menerima pesertaFase 1Sukarelawan sehat diterima
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07527923A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Cahaba Dermatology & Skin Health Center, Birmingham
Menerima pesertaFase 3
Usia 2 hingga 11 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06807281A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- AllerVie Clinical Research, Birmingham
- Cahaba Dermatology and Skin Health Center, Birmingham
Menerima pesertaFase 2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT07599813A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, Birmingham
Menerima pesertaFase 3
6 Months – 11 Years · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Cahaba Dermatology & Skin Health Center /ID# 263855, Birmingham
Menerima pesertaFase 3
Usia 18 hingga 63 · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT06389136A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Allervie Clinical Research, Birmingham
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Mei 2026 · NCT05995964Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.